A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, two-stage, multicenter Phase II study evaluating the
efficacy and safety of bevacizumab in women with platinum resistant, advanced (Stage III or
IV) EOC (epithelial ovarian cancer) or PPC (primary peritoneal cancer) that subsequently
progressed either during treatment with Doxil or Hycamtin therapy or within 3 months of
discontinuing treatment with Doxil or Hycamtin therapy.